These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 32980406)

  • 21. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.
    Yuen CK; Lam JY; Wong WM; Mak LF; Wang X; Chu H; Cai JP; Jin DY; To KK; Chan JF; Yuen KY; Kok KH
    Emerg Microbes Infect; 2020 Dec; 9(1):1418-1428. PubMed ID: 32529952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
    Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
    Hall DC; Ji HF
    Travel Med Infect Dis; 2020; 35():101646. PubMed ID: 32294562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
    Habtemariam S; Nabavi SF; Banach M; Berindan-Neagoe I; Sarkar K; Sil PC; Nabavi SM
    Arch Med Res; 2020 Oct; 51(7):733-735. PubMed ID: 32536457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution structures of the SARS-CoV-2 2'-
    Rosas-Lemus M; Minasov G; Shuvalova L; Inniss NL; Kiryukhina O; Brunzelle J; Satchell KJF
    Sci Signal; 2020 Sep; 13(651):. PubMed ID: 32994211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Architecture of a SARS-CoV-2 mini replication and transcription complex.
    Yan L; Zhang Y; Ge J; Zheng L; Gao Y; Wang T; Jia Z; Wang H; Huang Y; Li M; Wang Q; Rao Z; Lou Z
    Nat Commun; 2020 Nov; 11(1):5874. PubMed ID: 33208736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
    Elfiky AA
    Life Sci; 2020 May; 248():117477. PubMed ID: 32119961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repositioning of 8565 Existing Drugs for COVID-19.
    Gao K; Nguyen DD; Chen J; Wang R; Wei GW
    J Phys Chem Lett; 2020 Jul; 11(13):5373-5382. PubMed ID: 32543196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alkaloids from
    Borquaye LS; Gasu EN; Ampomah GB; Kyei LK; Amarh MA; Mensah CN; Nartey D; Commodore M; Adomako AK; Acheampong P; Mensah JO; Mormor DB; Aboagye CI
    Biomed Res Int; 2020; 2020():5324560. PubMed ID: 33029513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
    Iftikhar H; Ali HN; Farooq S; Naveed H; Shahzad-Ul-Hussan S
    Comput Biol Med; 2020 Jul; 122():103848. PubMed ID: 32658735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    F1000Res; 2020; 9():1166. PubMed ID: 33204411
    [No Abstract]   [Full Text] [Related]  

  • 39. Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex.
    Chen J; Malone B; Llewellyn E; Grasso M; Shelton PMM; Olinares PDB; Maruthi K; Eng ET; Vatandaslar H; Chait BT; Kapoor TM; Darst SA; Campbell EA
    Cell; 2020 Sep; 182(6):1560-1573.e13. PubMed ID: 32783916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Potential Inhibitors of the SARS-CoV-2 NSP13 Helicase via Structure-Based Ligand Design, Molecular Docking and Nonequilibrium Alchemical Simulations.
    Di Paco G; Macchiagodena M; Procacci P
    ChemMedChem; 2024 May; 19(10):e202400095. PubMed ID: 38456332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.